Short Interest in Moleculin Biotech, Inc. (NASDAQ:MBRX) Decreases By 42.7%

Moleculin Biotech, Inc. (NASDAQ:MBRX) saw a significant decline in short interest during the month of March. As of March 13th, there was short interest totaling 109,555 shares, a decline of 42.7% from the February 26th total of 191,156 shares. Currently, 5.4% of the shares of the company are sold short. Based on an average daily trading volume, of 152,358 shares, the short-interest ratio is presently 0.7 days.

Institutional Trading of Moleculin Biotech

An institutional investor recently bought a new position in Moleculin Biotech stock. Jane Street Group LLC purchased a new stake in Moleculin Biotech, Inc. (NASDAQ:MBRX) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 22,550 shares of the company’s stock, valued at approximately $75,000. Jane Street Group LLC owned approximately 1.11% of Moleculin Biotech as of its most recent filing with the Securities and Exchange Commission. 15.52% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms recently commented on MBRX. HC Wainwright reiterated a “buy” rating and issued a $22.00 target price on shares of Moleculin Biotech in a research report on Tuesday. Roth Mkm reiterated a “buy” rating on shares of Moleculin Biotech in a report on Monday, December 15th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Moleculin Biotech in a research note on Thursday, January 22nd. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $22.00.

Moleculin Biotech Stock Performance

Shares of NASDAQ:MBRX traded up $0.01 during trading hours on Friday, hitting $2.44. 82,210 shares of the company’s stock traded hands, compared to its average volume of 174,715. The company’s fifty day simple moving average is $3.26 and its two-hundred day simple moving average is $6.88. Moleculin Biotech has a 52 week low of $1.79 and a 52 week high of $28.61. The company has a market cap of $4.98 million, a price-to-earnings ratio of -0.07 and a beta of 1.73.

About Moleculin Biotech

Moleculin Biotech, Inc is a clinical-stage pharmaceutical company focused on the development of novel therapies for the treatment of highly resistant tumors and viral infections. The company’s research platform centers on the design and synthesis of drug candidates that target key cellular pathways in cancer cells and viral replication processes. By leveraging a proprietary chemistry approach, Moleculin aims to address diseases that have limited therapeutic options and high unmet medical need.

The company’s pipeline includes multiple product candidates at various stages of development.